Key result
AF medical management requires tailoring rate versus rhythm control to individual patient safety profiles.
Why the study?
How should pharmacological rate and rhythm control strategies be selected to safely manage patients with atrial fibrillation?
How should pharmacological rate and rhythm control strategies be selected to safely manage patients with atrial fibrillation?
Pharmacological therapy for atrial fibrillation remains centered on safety-driven drug selection, while newer data hint at the possibility of safely ceasing anticoagulation in patients with rigorous rhythm monitoring.
Answers are grounded in this paper and cite their sources.
Safety-driven antiarrhythmic selection remains central to AF care; leaves open whether rigorous rhythm control permits safe anticoagulation cessation.
Pharmacological therapy remains the primary approach to atrial fibrillation (AF). Management of all AF patients includes the decision on rate or rhythm control. The latter means antiarrhythmic drugs application that are being selected primarily by safety reasons and depend on individual characteristics of patients. The article presents a brief description of efficacy and safety of antiarrhythmics themselves and other drugs for sinus rhythm control in AF. Novel data shows possibility to decrease stroke risk and mortality, and to cease anticoagulation in more thorough sinus rhythm retention.
No takes yet. Share an insight, caveat, or question.
Kanorsky et al. (2017) conducted a review in Atrial fibrillation. Pharmacological therapy (antiarrhythmic and rate-controlling drugs) was evaluated. Pharmacological management of atrial fibrillation involves choosing between rate or rhythm control, with antiarrhythmic drug selection driven primarily by patient safety and individual characteristics.
Synapse has enriched 10 related papers. Consider them for comparative context: